IRADIMED CORPORATION Earnings Call Transcripts
Fiscal Year 2026
-
Q2 revenue reached $20.5M with strong demand for the new 3870 MRI IV pump, especially quad systems, driving bookings to more than double shipments. Gross margin dipped to 74% due to ramp-up costs but is expected to recover as efficiencies improve. Full-year guidance is reaffirmed.
-
Q2 2025 delivered record revenue and earnings growth, driven by strong pump and monitor sales, robust margins, and a record backlog. FDA clearance of the new MRidium 3870 pump sets the stage for accelerated growth and a raised 2025 outlook.
Fiscal Year 2025
-
Q4 2025 revenue rose 17% year-over-year to $22.7 million, with strong growth across all product lines and robust gross margins. The new 3870 pump launch is set to drive significant revenue growth in 2026, supported by positive early feedback and a large replacement market opportunity.
-
Q2 2025 delivered record revenue and earnings growth, driven by strong pump and monitor sales. FDA clearance of the new 3870 IV pump sets the stage for accelerated growth, with raised guidance and a $100M revenue run rate targeted for 2026.
-
Q2 2025 delivered record revenue and earnings growth, driven by strong pump and monitoring sales. FDA clearance of the 3870 pump sets up a major replacement cycle and higher ASPs, supporting raised 2025 guidance and a $100M+ run rate outlook for 2026.
-
Record Q1 2025 revenue rose 11% year-over-year, led by strong pump and disposable sales, with gross margin steady at 76.1%. Guidance for 2025 is reaffirmed, and the new facility and 3870 MRI IV pump are on track for key milestones.
-
Revenue reached $72 million in 2024, with strong growth expected as a new MRI-safe IV pump launches and a major replacement cycle begins. A new facility will support increased demand, and product innovation plus high barriers to entry position the business for multi-year expansion.
Fiscal Year 2024
-
Record Q4 2024 revenue and earnings were driven by strong pump sales and increased domestic monitor bookings. FY 2025 guidance projects continued growth, with a focus on the monitor segment and new product launches, while gross margins are expected to remain stable.
-
Q3 2024 delivered record revenue of $18.3M, up 11% year-over-year, driven by strong IV pump sales and robust gross margins. Guidance for 2024 was raised, with a product mix shift expected in 2025 as the new pump launch approaches.
-
Q2 2024 delivered record revenue of $17.9M (+11% YoY), gross margin of 78.1%, and strong EPS growth. Pump sales surged 52%, while monitor and FMD lines showed steady progress. Guidance for 2024 is reiterated, with new product launches and facility expansion on track.